A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by stimulating the mother’s immune system to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity provides newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst observing that protection can still occur even if given later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Antibodies from the mother passed through placenta safeguard newborns from day one
- Coverage achievable with 2-week gap before premature birth
- Vaccination in third trimester still provides significant protection for infants
Persuasive evidence from the latest research
The effectiveness of the RSV vaccine administered during pregnancy has been confirmed through a extensive research programme conducted across England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month period, providing comprehensive and reliable information of the vaccine’s actual performance. The study’s results have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their most vulnerable early months. The breadth of this investigation provides healthcare professionals and expectant parents with assurance in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results present a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV during the study period, with the great majority being infants whose mothers had not been given the vaccination. This stark contrast highlights the vaccine’s vital importance in preventing serious illness in newborns. The decrease in hospital admissions exceeding 80 per cent represents a significant public health achievement, potentially preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme introduced in the UK in 2024.
Study methodology and scope
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The sizeable sample and thorough nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology assessed real-world outcomes rather than experimental conditions, providing real-world data of how the vaccine works when administered across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the risks
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for infected babies to feed and breathe adequately. Parents commonly see their babies visibly struggling, their chests rising whilst they work to get sufficient oxygen into their compromised lungs. Whilst most newborns get better with palliative treatment, a small but significant group succumb from RSV complications yearly, making immunisation programmes a essential public health objective for safeguarding the most vulnerable and youngest individuals in the population.
- RSV triggers lung inflammation, leading to serious respiratory problems in babies
- Approximately half of infants acquire the virus in their first few months of life
- Symptoms span from mild colds to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- Small numbers of babies succumb to RSV related complications annually in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have stressed the importance of pregnant women receiving their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has underscored that the timing is essential for guaranteeing newborns receive the most robust immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery delivers nearly 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies through the placenta.
The messaging from public health bodies remains clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This adaptable strategy recognises the realities of pregnancy and childbirth whilst ensuring strong protection for vulnerable newborns during their most critical early months when RSV poses the greatest risk of severe infection.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Certain regions have attained higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to increase awareness and availability of the jab. These geographical variations reflect variations in medical facilities, engagement approaches, and local engagement efforts, though the overall statistics shows robust and reliable protection regardless of geographical location.
- NHS trusts deploying multiple messaging strategies to connect with women during pregnancy
- Geographic variations in vaccination coverage levels in different parts of England require targeted improvement
- Regional health providers modifying schemes to meet community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness delivers concrete gains for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the rollout of this protective measure, the 80% decrease in admissions means thousands of infants shielded from severe infection. Parents no longer face the distressing scenario of seeing their babies gasping for air or struggle to eat, symptoms that define critical RSV illness. The vaccine has markedly changed the terrain of neonatal lung health, offering expectant mothers a preventative option to shield their most vulnerable children during those vital initial period.
For families like that of Malachi, whose acute RSV infection resulted in profound brain damage, the vaccine’s introduction carries deep personal significance. His mother’s promotion of the jab highlights the profound consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has given considerable reassurance to women in pregnancy during their final trimester, changing what was once an predictable seasonal threat into a controllable health concern.